Where Ambrx Biopharma Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Ambrx Biopharma (NASDAQ:AMAM) in the last quarter, with 1 bullish, 2 somewhat bullish, and 1 indifferent. Over the past 3 months, 4 analysts have offered 12-month price targets for the company, with an average price target of $22.5, a high of $29.00, and a low of $10.00. The average price target has increased by 275.0% over the past month.
September 13, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ambrx Biopharma has received mixed ratings from analysts, with an average 12-month price target of $22.5. The average price target has increased by 275.0% over the past month.
The mixed ratings from analysts indicate uncertainty about the company's performance. However, the significant increase in the average price target over the past month suggests that analysts are becoming more optimistic about the company's prospects, which could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100